ANIX Earnings Date: Jan 11, 2027 (Estimated) — Anixa Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is ANIX's next earnings date?
Anixa Biosciences, Inc. (ANIX) is expected to report Q4 2026 earnings on Monday, January 11, 2027 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.08.
How did ANIX do in its last earnings report?
In its most recent report on Sep 9, 2026 (Q3 2026), Anixa Biosciences, Inc. posted EPS of -$0.08 versus the -$0.08 estimate, a beat of 0.0%. Revenue was $0. The stock's 1-day post-earnings move was -2.8%.
How much does ANIX stock move after earnings?
ANIX beat EPS estimates in 6 of its last 7 reported quarters. Over the last 8 reports the stock moved an average of 2.4% (up or down) in the day after earnings.
About Anixa Biosciences, Inc.
Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel chimeric endocrine receptor T-cell (CER-T) technology, an innovative adaptation of CAR-T, specifically for ovarian cancer treatment. The company is also engaged in the discovery and development of antiviral drug candidates to combat COVID-19, focusing on the inhibition of specific viral protein functions. On the vaccine front, Anixa's initiatives include a vaccine designed to target triple-negative breast cancer and a distinct preventative vaccine aimed at ovarian cancer. Beyond specific therapies and vaccines, Anixa also has immuno-therapy drugs for various cancers in its development portfolio. A key collaboration exists with MolGenie GmbH for the discovery and development of its COVID-19 antiviral candidates. Tracing its origins back to an incorporation in 1982, the company initially operated as ITUS Corporation before adopting the name Anixa Biosciences, Inc. in October 2018. It is headquartered in San Jose, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-09 | Q3 2026 | -0.08 | -0.08 | +0.00% | $0 | ✅ Beat | -2.83% | -8.13% | +2.83% |
| 2026-06-10 | Q2 2026 | -0.10 | -0.07 | +30.00% | $0 | ✅ Beat | +5.53% | +14.47% | +30.21% |
| 2026-03-09 | Q1 2026 | -0.09 | -0.08 | +11.11% | $0 | ✅ Beat | +0.00% | -4.70% | -8.39% |
| 2026-01-12 | Q4 2025 | -0.09 | -0.09 | +0.00% | $0 | ➖ Inline | +3.80% | -1.58% | -10.13% |
| 2025-09-10 | Q3 2025 | -0.10 | -0.07 | +30.00% | $0 | ✅ Beat | -2.32% | +10.93% | +62.91% |
| 2025-03-11 | Q1 2025 | — | -0.10 | — | $0 | — | +0.75% | +14.66% | +1.13% |
| 2025-01-10 | Q4 2024 | -0.11 | -0.09 | +18.18% | $0 | ✅ Beat | -2.67% | +7.11% | +37.78% |
| 2024-09-06 | Q3 2024 | -0.11 | -0.10 | +9.09% | $0 | ✅ Beat | -1.25% | +4.36% | -2.49% |
Showing last 8 quarters.